2025-11-30 - Analysis Report
Okay, here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the data you provided.

**1) Return Rate Comparison**

*   **Company Overview:** Teladoc Health Inc. is a telehealth company offering virtual healthcare services.
*   **TDOC Cumulative Return:** -62.97%
*   **S&P 500 (VOO) Cumulative Return:** 102.96%
*   **Divergence:** -162.3 (Relative Divergence: 1.0)

**Analysis:** TDOC has significantly underperformed the S&P 500. The divergence is a large negative number, indicating substantial underperformance. A Relative Divergence of 1.0 means it is located at the top percentile of past data, but the negative number still indicates it's underperforming the VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 77.0%   | 70.4%  | 51.0%   | -0.1  | 6.2    |
| 2016-2018  | 101.0%  | 69.4%  | 86.0%   | -0.1  | 8.8    |
| 2017-2019  | 141.0%  | 73.8%  | 118.0%  | 0.3   | 14.9   |
| 2018-2020  | 105.0%  | 80.9%  | 81.0%   | 0.3   | 35.5   |
| 2019-2021  | -78.0%  | 80.9%  | -125.0% | 0.3   | 16.3   |
| 2020-2022  | -252.0% | 85.9%  | -251.0% | -0.9  | 4.2    |
| 2021-2023  | -315.0% | 85.9%  | -316.0% | -1.8  | 3.8    |
| 2022-2024  | -93.0%  | 85.9%  | -113.0% | -1.9  | 1.6    |
| 2023-2025  | -34.0%  | 81.6%  | -100.0% | -0.8  | 1.4    |

**Analysis:**

*   **CAGR:** Compounded Annual Growth Rate. The early years (2015-2020) show impressive growth, but the recent years (2019-2025) reveal massive negative growth, indicating significant losses.
*   **MDD:** Maximum Drawdown. This indicates the largest peak-to-trough decline during the period. TDOC has consistently high MDD values (70%+) indicating high volatility and risk.
*   **Alpha:** Measures the stock's performance compared to a benchmark index.  The Alpha values are largely negative in recent years, indicating substantial underperformance compared to the benchmark.
*   **Beta:** Measures the stock's volatility relative to the market. Beta values close to 0 (especially negative values) means TDOC is not correlated with the market, or inversely correlated. As the market rose, TDOC fell.
*   **Cap(B):** Market Capitalization in Billions. The market cap has decreased significantly, especially over the past few years, indicating a loss of investor confidence.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 7.59
*   **Last Market Change:** Price = 7.59, Previous Close = 7.45, Change = 1.88%
*   **5-day SMA:** 7.342
*   **20-day SMA:** 7.4393
*   **60-day SMA:** 8.0195

**Analysis:** The stock is currently trading above its 5-day and 20-day SMAs, but below its 60-day SMA.  The last-market change indicates a recent upward movement in the stock price. This suggests a potential short-term upward trend, but it's still below its medium-term average.

**3) RSI, PPO and MRI Analysis**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 51.28
*   **PPO:** 0.7739
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (134 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 0.9 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** -10009.8

**Analysis:**

*   **MRI:** A high MRI suggests that the model indicates that investment in TDOC is considered "high investment recommended." This is contradictory to all of the other metrics.
*   **RSI:** The RSI of 51.28 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** A positive PPO suggests that the short-term moving average is above the long-term moving average, which could signal a potential uptrend, although the value is close to zero.
*   **Hybrid Signal:** The signal recommends buying 100% of available cash, indicating an extremely safe strategy.
*   **Divergence Change:** Recent improvement in relative divergence indicates a short-term positive movement.
*   **Expected Return:** The extremely negative expected return is extremely concerning and indicates the model is projecting very significant losses if an investment is made now.

**4) Recent News & Significant Events**

*   **Mixed Sentiment:** The news articles present a mixed outlook. Some focus on valuation assessments after a short-term price rebound, while others express fading hope and long/short opportunities.
*   **Analyst Coverage:** B of A Securities maintains a neutral recommendation.
*   **Motley Fool Article:** Discusses the possibility of the stock being on the road to recovery.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (Mean = 2.65)
*   **Target Price (avg/high/low):** 9.21 / 12.00 / 7.00

**Analysis:** The analyst consensus is "Hold" with an average target price of $9.21, which is slightly above the current price, suggesting some potential upside. However, the low target price of $7.00 indicates that some analysts believe the stock could decline.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-10-30 | -0.28 | 0.63 B$ |
| 2025-07-30 | -0.19 | 0.63 B$ |
| 2025-05-01 | -0.53 | 0.63 B$ |
| 2024-10-31 | -0.19 | 0.64 B$ |
| 2025-10-30 | -0.19 | 0.64 B$ |

**Analysis:**

*   **EPS:** Teladoc has consistently reported negative EPS, indicating a lack of profitability.
*   **Revenue:** Revenue has been relatively stable around $0.63-$0.64 billion.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.63B   | 70.12%        |
| 2025-06-30 | $0.63B   | 69.85%        |
| 2025-03-31 | $0.63B   | 68.73%        |
| 2024-12-31 | $0.64B   | 70.50%        |
| 2024-09-30 | $0.64B   | 71.94%        |

**Analysis:**

*   Revenue has been consistent.
*   Profit margin has been consistent as well.

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-09-30 | $1.39B   | -3.56%  |
| 2025-06-30 | $1.42B   | -2.30%  |
| 2025-03-31 | $1.43B   | -6.52%  |
| 2024-12-31 | $1.49B   | -3.25%  |
| 2024-09-30 | $1.51B   | -2.21%  |

**Analysis:**

*   Equity has been slowly decreasing over the past several quarters.
*   ROE has been consistently negative, indicating the company is not generating returns on shareholder equity.

**7) Comprehensive Analysis**

**Summary:**

Teladoc Health Inc. (TDOC) presents a concerning picture. While there has been a recent short-term rebound, the company has significantly underperformed the S&P 500 over the longer term. The negative CAGR, high MDD, negative Alpha, negative EPS, negative ROE and declining Equity highlights a concerning trend.

**Key Concerns:**

*   **Sustained Losses:** The company is not profitable, with consistent negative EPS and ROE.
*   **Underperformance:** The stock has significantly underperformed the S&P 500.
*   **High Volatility:** The MDD shows high volatility, indicating a risky investment.
*   **Decreasing Equity:** The company's equity has been declining.
*   **Mixed Signals:** The Market Risk Indicator (MRI) suggests high investment, contradictory to all of the other negative metrics.

**Potential Positives:**

*   **Recent Short-Term Rebound:** The last-market change and improvement in relative divergence indicate a potential short-term positive trend.
*   **Analyst Target Price:** The average analyst target price suggests some potential upside.
*   **Hybrid Signal:** The signal recommends buying 100% of available cash, indicating an extremely safe strategy, but is also contradictory to all of the other negative metrics.

**Conclusion:**

While the recent short-term rebound and analyst target price offer a glimmer of hope, the overall picture for TDOC is negative. The company needs to demonstrate a path to profitability and address the underlying issues causing its underperformance. The extremely negative expected return indicates caution, and investors should carefully consider the risks before investing. The MRI, which contradicts all other negative metrics, should be further examined before considering investment.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.